Citations (37)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Tao Zhu, Tianming Yuan, Huimin Yu, Weizhong Gu, Xi Chen & Peifang Jiang. (2020) The phosphodiesterase-4 inhibitor Rolipram promotes cognitive function recovery in prenatal Escherichia coli infected offspring. The Journal of Maternal-Fetal & Neonatal Medicine 33:13, pages 2166-2175.
Read now
Read now
Jos Prickaerts, Pim R. A. Heckman & Arjan Blokland. (2017) Investigational phosphodiesterase inhibitors in phase I and phase II clinical trials for Alzheimer’s disease. Expert Opinion on Investigational Drugs 26:9, pages 1033-1048.
Read now
Read now
Wito Richter, Frank S. Menniti, Han-Ting Zhang & Marco Conti. (2013) PDE4 as a target for cognition enhancement. Expert Opinion on Therapeutic Targets 17:9, pages 1011-1027.
Read now
Read now
Articles from other publishers (34)
Heena Khan, Chanchal Tiwari, Amarjot Kaur Grewal, Thakur Gurjeet Singh, Simran Chauhan & Gaber El-Saber Batiha. (2022) Pharmacological modulation of phosphodiesterase-7 as a novel strategy for neurodegenerative disorders. Inflammopharmacology 30:6, pages 2051-2061.
Crossref
Crossref
Michel Rasmussen, Charlotte Welinder, Frank Schwede & Per Ekström. (2021) The stereospecific interaction sites and target specificity of cGMP analogs in mouse cortex. Chemical Biology & Drug Design 99:2, pages 206-221.
Crossref
Crossref
Abigail Boyd, Ileana Aragon, Justin Rich, Will McDonough, Marianna Oditt, Daniel Irelan, Edward Fiedler, Lina Abou Saleh & Wito Richter. (2021) Assessment of PDE4 Inhibitor-Induced Hypothermia as a Correlate of Nausea in Mice. Biology 10:12, pages 1355.
Crossref
Crossref
Natalia A. Sanina, Yuliya A. Isaeva, Andrey N. Utenyshev, Pavel V. Dorovatovskii, Nickolai S. Ovanesyan, Nina S. Emel'yanova, Olesya V. Pokidova, Liliya V. Tat'yanenko, Il'ya V. Sulimenkov, Alexandr I. Kotel'nikov & Sergey M. Aldoshin. (2021) Synthesis, structure, and PDE inhibiting activity of the anionic DNIC with 5-(3-pyridyl)-4H-1,2,4-triazole-3-thiolyl, the nitric oxide donor. Inorganica Chimica Acta 527, pages 120559.
Crossref
Crossref
James Gilleen, Yakub Farah, Cate Davison, Sarah Kerins, Lorena Valdearenas, Tolga Uz, Gez Lahu, Max Tsai, Frank Ogrinc, Avi Reichenberg, Steve C. Williams, Mitul A. Mehta & Sukhi S. Shergill. (2018) An experimental medicine study of the phosphodiesterase-4 inhibitor, roflumilast, on working memory-related brain activity and episodic memory in schizophrenia patients. Psychopharmacology 238:5, pages 1279-1289.
Crossref
Crossref
Susann Schröder, Matthias Scheunemann, Barbara Wenzel & Peter Brust. (2021) Challenges on Cyclic Nucleotide Phosphodiesterases Imaging with Positron Emission Tomography: Novel Radioligands and (Pre-)Clinical Insights since 2016. International Journal of Molecular Sciences 22:8, pages 3832.
Crossref
Crossref
Gary Tresadern, Ingrid Velter, Andrés A. Trabanco, Frans Van den Keybus, Gregor J. Macdonald, Marijke V. F. Somers, Greet Vanhoof, Philip M. LeonardMarieke B. A. C. LamersYves E. M. Van Roosbroeck & Peter J. J. A. Buijnsters. (2020)
[1,2,4]Triazolo[1,5-
a
]pyrimidine Phosphodiesterase 2A Inhibitors: Structure and Free-Energy Perturbation-Guided Exploration
. Journal of Medicinal Chemistry 63:21, pages 12887-12910.
Crossref
Crossref
Jie Xiang, Xin Wang, Yuan Gao, Ting Li, Rui Cao, Ting Yan, Yunxiao Ma, Yan Niu, Jiayue Xue & Bin Wang. (2020) Phosphodiesterase 4D Gene Modifies the Functional Network of Patients With Mild Cognitive Impairment and Alzheimer’s Disease. Frontiers in Genetics 11.
Crossref
Crossref
Giovanni Ribaudo, Alberto Ongaro, Giuseppe Zagotto, Maurizio Memo & Alessandra Gianoncelli. (2020) Therapeutic Potential of Phosphodiesterase Inhibitors against Neurodegeneration: The Perspective of the Medicinal Chemist. ACS Chemical Neuroscience 11:12, pages 1726-1739.
Crossref
Crossref
Amy J. Tibbo & George S. Baillie. (2020) Phosphodiesterase 4B: Master Regulator of Brain Signaling. Cells 9:5, pages 1254.
Crossref
Crossref
Alejandro Castán, Ramón Badorrey, José A. Díez, Claus T. Christoffersen, Lars K. Rasmussen, Jan Kehler, Ralf Köhler, José A. Gálvez & María D. Díaz-de-Villegas. (2020)
Debenzylative Cycloetherification as a Synthetic Tool in the Diastereoselective Synthesis of 3,6-Disubstituted Hexahydro-2
H
-furo[3,2-
b
]pyrroles, PDE1 Enzyme Inhibitors with an Antiproliferative Effect on Melanoma Cells
. The Journal of Organic Chemistry 85:9, pages 5941-5951.
Crossref
Crossref
Owen Sanders. (2020) Sildenafil for the Treatment of Alzheimer’s Disease: A Systematic Review. Journal of Alzheimer's Disease Reports 4:1, pages 91-106.
Crossref
Crossref
Guilherme Martins Silva, Mariana Pegrucci Barcelos, João Gabriel Curtolo Poiani, Lorane Izabel da Silva Hage‐Melim & Carlos Henrique Tomich de Paula da Silva. (2019) Allosteric Modulators of Potential Targets Related to Alzheimer's Disease: a Review. ChemMedChem 14:16, pages 1467-1483.
Crossref
Crossref
N. A. Beregovoi, M. V. Starostina & T. V. Lipina. (2019) Effects of Specific Inhibitor of Phosphodiesterase 7 at the Late Stage of Long-Term Potentiation in Murine Hippocampal Slices. Bulletin of Experimental Biology and Medicine 167:4, pages 467-469.
Crossref
Crossref
Ritawidya, Ludwig, Briel, Brust & Scheunemann. (2019) Synthesis and In Vitro Evaluation of 8-Pyridinyl-Substituted Benzo[e]imidazo[2,1-c][1,2,4]triazines as Phosphodiesterase 2A Inhibitors. Molecules 24:15, pages 2791.
Crossref
Crossref
Melissa Schepers, Assia Tiane, Dean Paes, Selien Sanchez, Ben Rombaut, Elisabeth Piccart, Bart P. F. Rutten, Bert Brône, Niels Hellings, Jos Prickaerts & Tim Vanmierlo. (2019) Targeting Phosphodiesterases—Towards a Tailor-Made Approach in Multiple Sclerosis Treatment. Frontiers in Immunology 10.
Crossref
Crossref
Simon Chiu. (2017) Exploring Standardized Zembrin® Extracts from the South African plant Sceletium tortuosum in Dual Targeting Phosphodiesterase-4 (PDE-4) and Serotonin Reuptake Inhibition as potential treatment in Schizophrenia. International Journal of Complementary & Alternative Medicine 6:5.
Crossref
Crossref
C. Dorner-Ciossek, K. S. Kroker & H. Rosenbrock. 2017. Phosphodiesterases: CNS Functions and Diseases. Phosphodiesterases: CNS Functions and Diseases
231
254
.
Yu-Wen Li, Matthew A. Seager, Trevor Wojcik, Karen Heman, Thaddeus F. Molski, Alda Fernandes, Shaun Langdon, Annapurna Pendri, Samuel Gerritz, Yuan Tian, Yang Hong, Lizbeth Gallagher, James R. Merritt, Chongwu Zhang, Ryan Westphal, Robert Zaczek, John E. Macor, Joanne J. Bronson & Nicholas J. Lodge. (2016) Biochemical and behavioral effects of PDE10A inhibitors: Relationship to target site occupancy. Neuropharmacology 102, pages 121-135.
Crossref
Crossref
E. Bollen, S. Akkerman, D. Puzzo, W. Gulisano, A. Palmeri, R. D'Hooge, D. Balschun, H.W.M. Steinbusch, A. Blokland & J. Prickaerts. (2015) Object memory enhancement by combining sub-efficacious doses of specific phosphodiesterase inhibitors. Neuropharmacology 95, pages 361-366.
Crossref
Crossref
P.R.A. Heckman, A. Blokland, J. Ramaekers & J. Prickaerts. (2015) PDE and cognitive processing: Beyond the memory domain. Neurobiology of Learning and Memory 119, pages 108-122.
Crossref
Crossref
F Ahmad, T Murata, K Shimizu, E Degerman, D Maurice & V Manganiello. (2014) Cyclic Nucleotide Phosphodiesterases: important signaling modulators and therapeutic targets. Oral Diseases 21:1.
Crossref
Crossref
Olga Bruno, Roberta Ricciarelli, Jos Prickaerts, Linda Parker & Ernesto Fedele. (2014) PDE4D inhibitors: A potential strategy for the treatment of memory impairment?. Neuropharmacology 85, pages 290-292.
Crossref
Crossref
Peter Buijnsters, Meri De Angelis, Xavier Langlois, Frederik J. R. Rombouts, Wendy Sanderson, Gary Tresadern, Alison RitchieAndrés A. Trabanco, Greet VanHoof, Yves Van Roosbroeck & José-Ignacio Andrés. (2014) Structure-Based Design of a Potent, Selective, and Brain Penetrating PDE2 Inhibitor with Demonstrated Target Engagement. ACS Medicinal Chemistry Letters 5:9, pages 1049-1053.
Crossref
Crossref
Katja S. Kroker, Chantal Mathis, Anelise Marti, Jean-Christophe Cassel, Holger Rosenbrock & Cornelia Dorner-Ciossek. (2014) PDE9A inhibition rescues amyloid beta-induced deficits in synaptic plasticity and cognition. Neurobiology of Aging 35:9, pages 2072-2078.
Crossref
Crossref
Sarah A Stern, Amy S Kohtz, Gabriella Pollonini & Cristina M Alberini. (2014) Enhancement of Memories by Systemic Administration of Insulin-Like Growth Factor II. Neuropsychopharmacology 39:9, pages 2179-2190.
Crossref
Crossref
José Manuel Bartolomé-Nebreda, Francisca Delgado, María Luz Martín-Martín, Carlos M. Martínez-Viturro, Joaquín Pastor, Han Min Tong, Laura Iturrino, Gregor J. Macdonald, Wendy Sanderson, Anton Megens, Xavier Langlois, Marijke Somers, Greet Vanhoof & Susana Conde-Ceide. (2014) Discovery of a Potent, Selective, and Orally Active Phosphodiesterase 10A Inhibitor for the Potential Treatment of Schizophrenia. Journal of Medicinal Chemistry 57:10, pages 4196-4212.
Crossref
Crossref
Monalisa F. AzevedoFabio R. FauczEirini BimpakiAnelia HorvathIsaac LevyRodrigo B. de AlexandreFaiyaz AhmadVincent ManganielloConstantine A. Stratakis. (2014) Clinical and Molecular Genetics of the Phosphodiesterases (PDEs). Endocrine Reviews 35:2, pages 195-233.
Crossref
Crossref
Donald H. Maurice, Hengming Ke, Faiyaz Ahmad, Yousheng Wang, Jay Chung & Vincent C. Manganiello. (2014) Advances in targeting cyclic nucleotide phosphodiesterases. Nature Reviews Drug Discovery 13:4, pages 290-314.
Crossref
Crossref
Simon Chiu, Nigel Gericke, Michel Farina-Woodbury, Vladimir Badmaev, Hana Raheb, Kristen Terpstra, Joalex Antongiorgi, Yves Bureau, Zack Cernovsky, Jirui Hou, Veronica Sanchez, Marissa Williams, John Copen, Mariwan Husni & Liz Goble. (2014)
Proof-of-Concept Randomized Controlled Study of Cognition Effects of the Proprietary Extract
Sceletium tortuosum
(Zembrin) Targeting Phosphodiesterase-4 in Cognitively Healthy Subjects: Implications for Alzheimer’s Dementia
. Evidence-Based Complementary and Alternative Medicine 2014, pages 1-9.
Crossref
Crossref
John M. Humphrey, Eddie Yang, Christopher W. am Ende, Eric P. Arnold, Jenna L. Head, Stephen Jenkinson, Lorraine A. Lebel, Spiros Liras, Jayvardhan Pandit, Brian Samas, Felix Vajdos, Samuel P. Simons, Artem Evdokimov, Mahmoud Mansour & Frank S. Menniti. (2014) Small-molecule phosphodiesterase probes: discovery of potent and selective CNS-penetrable quinazoline inhibitors of PDE1. Med. Chem. Commun. 5:9, pages 1290-1296.
Crossref
Crossref
Thomas M. Sanderson & Emanuele Sher. (2013) The role of phosphodiesterases in hippocampal synaptic plasticity. Neuropharmacology 74, pages 86-95.
Crossref
Crossref
O.A.H. Reneerkens, A. Sambeth, A. Blokland & J. Prickaerts. (2013) PDE2 and PDE10, but not PDE5, inhibition affect basic auditory information processing in rats. Behavioural Brain Research 250, pages 251-256.
Crossref
Crossref
Ana Martinez & Carmen Gil. 2013. Emerging Drugs and Targets for Parkinson’s Disease. Emerging Drugs and Targets for Parkinson’s Disease
294
307
.